focus -WSS

focus

author：fashion 2025-09-06 04:33:46 - browse：299

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Mitch McConnell episode has important public health takeaway

WSS

How to ethically and practically extend health care to all

‘Oppenheimer’ and the risks of AI in health care

Florida officials tell state schools to teach AP Psychology 'in its entirety'

National panel will explore requiring free Covid tests

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

No plane should take off without an EpiPen onboard

hotspot

focus

explore

The high cost of giving birth even with insurance

Micronoma's microbiome cancer diagnostic approach under fire

Anesthesiologist group: stop taking Ozempic before surgery

Heart disease in astronauts blamed on cosmic radiation

Jerome Adams on the need for new antivirals for Covid

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Continuity nursing helped my family in our darkest PICU moments

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

The high cost of giving birth even with insurance

Study links childhood stress with decline in older age

hotspot

Pharma showers House GOP doctor with campaign cash

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Alnylam reports growth in sales of rare disease treatments

Heart disease in astronauts blamed on cosmic radiation

H.R. 3 is the wrong path to lower drug costs

EQRx, failed developer of low

focus

hotspot

hotspot

Wikipedia